Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.
Age
12 - 18 years
Sex
ALL
Healthy Volunteers
No
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Start Date
December 29, 2025
Primary Completion Date
October 31, 2027
Completion Date
October 31, 2028
Last Updated
January 8, 2026
180
ESTIMATED participants
Placebo
DRUG
IBI362
DRUG
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions